KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Receivables (2019 - 2025)

GoodRx Holdings' Receivables history spans 7 years, with the latest figure at $235.7 million for Q4 2025.

  • For Q4 2025, Receivables rose 61.54% year-over-year to $235.7 million; the TTM value through Dec 2025 reached $235.7 million, up 61.54%, while the annual FY2025 figure was $235.7 million, 61.54% up from the prior year.
  • Receivables for Q4 2025 was $235.7 million at GoodRx Holdings, up from $203.7 million in the prior quarter.
  • Across five years, Receivables topped out at $235.7 million in Q4 2025 and bottomed at $74.4 million in Q1 2021.
  • The 5-year median for Receivables is $123.3 million (2022), against an average of $136.9 million.
  • The largest annual shift saw Receivables surged 65.7% in 2022 before it dropped 5.55% in 2023.
  • A 5-year view of Receivables shows it stood at $118.1 million in 2021, then fell by 0.8% to $117.1 million in 2022, then increased by 22.59% to $143.6 million in 2023, then grew by 1.62% to $145.9 million in 2024, then surged by 61.54% to $235.7 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Receivables are $235.7 million (Q4 2025), $203.7 million (Q3 2025), and $189.0 million (Q2 2025).